Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Terminated · Phase 2 · NCT06341712
Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
At a glance
- Research payments reported, 2025
- $93,345
- U.S. investigators named
- 4
- Sites paid
- 5
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Ipsen
- Tested
- Cabozantinib (drug), Best Supportive Care (BSC) (other), Best Supportive Care (BSC) (other)
- Dates
- Started 2024-11-22; completion 2026-02-27
- Results posted
- Yes
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery. Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid. Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young adults. In this study, participants will receive either cabozantinib and best supportive care or the best supportive care alone. Best supportive care will be provided at the investigator's discretio…
From ClinicalTrials.gov, last updated 2026-10-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Innovation reported $93,345 in research payments for this study in 2025 (42 payments).
Products named: Cabometyx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Allison K. Pribnow, MD Pediatric Hematology & Oncology · Palo Alto, CA
- Joanne P. Lagmay, MD Pediatric Hematology & Oncology · Gainesville, FL
- Stephan W. Anderson, M.D. Radiology · Boston, MA
- Erin M. Trovillion, MD Pediatrics · Charlotte, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Florida $38,110
- The Board of Trustees of the Leland Stanford Junior University $22,955
- Wake Forest University Health Science $20,240
- Board of Trustees of the Leland Stanford $5,440
- $5,394
- Boston Imaging Core Lab, Llc $1,207
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.